Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Envoy MedicalCOCH +3.18%24 EBIT per Share is $-0.81 as of Mar. 2026. GuruFocus rates COCH with a GF Score™ of 24/100 and a GF Value™ of $1.13 (Possible Value Trap). The stock has 6 warning signs investors should review. Among 687 Medical Devices & Instruments companies, Envoy Medical ranks worse than 67.54% on this metric.
Envoy Medical's EBIT per Share for the
three
months ended in Mar. 2026 was $-0.06.
Its EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2026 was $-0.81.
During the past 3 years, the average EBIT per Share Growth Rate was -3.70% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.
The historical rank and industry rank for Envoy Medical's EBIT per Share or its related term are showing as below:
COCH'
s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: -14.8 Med: -9.25 Max: -3.7
Current: -3.7
During the past 5 years, the highest 3-Year average EBIT per Share Growth Rate of Envoy Medical was -3.70% per year. The lowest was -14.80% per year. And the median was -9.25% per year.
COCH's 3-Year EBIT Growth Rate is ranked worse than 67.54% of 687
companies
in the Medical Devices & Instruments industry
Industry Median: 9.1
vs COCH: -3.70
Envoy Medical's EBIT for the
three
months ended in Mar. 2026 was $-4.35 Mil.
Envoy Medical (NAS:COCH) EBIT per Share Explanation
EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.
Envoy Medical EBIT per Share Related Terms
Envoy Medical EBIT per Share Historical Data
* Premium members only.
The historical data trend for Envoy Medical's EBIT per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.81
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Envoy Medical (COCH) has a EBIT per Share of $-0.81 as of Mar. 2026. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Envoy Medical and its competitors. According to the industry distribution chart, Envoy Medical ranks #464 out of 687 companies in the Medical Devices & Instruments industry, placing it in the top 67.5%.
Is Envoy Medical's EBIT per Share too high?
Envoy Medical's current EBIT per Share is $-0.81. Based on the distribution chart, Envoy Medical ranks #464 out of 687 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, Envoy Medical has a GF Score™ of 24/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Envoy Medical's EBIT per Share compare to SRTS and QTI?
According to the Medical Devices & Instruments industry distribution chart, Envoy Medical ranks #464 out of 687 companies for EBIT per Share. This places Envoy Medical in the lower half of its industry. The industry median EBIT per Share is 9.10. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT per Share for a Medical Devices & Instruments company?
The median EBIT per Share among Medical Devices & Instruments companies is 9.10, based on 687 companies in the industry. Companies in the top quartile (top 25%) have a EBIT per Share significantly above this median, while those in the bottom quartile fall well below. However, EBIT per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT per Share mean?
A high EBIT per Share can signal that a stock is expensive relative to its fundamentals. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Envoy Medical and its competitors. For the Medical Devices & Instruments industry, the median EBIT per Share is 9.10 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Envoy Medical's current EBIT per Share is $-0.81. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Envoy Medical stock overvalued right now?
Based on GuruFocus' analysis, Envoy Medical (COCH) is currently considered Possible Value Trap. The stock's GF Value™ is $1.13, compared to a current price of $0.76 — trading 32.7% below its estimated fair value. The current EBIT per Share is $-0.81. Envoy Medical's overall GF Score™ is 24/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT per Share calculated?
EBIT per Share is calculated from a company's financial statements. For Envoy Medical (COCH), the current EBIT per Share is $-0.81 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Envoy Medical (COCH) Overvalued in 2026?
Based on GuruFocus' analysis, Envoy Medical stock appears to be undervalued.
The current stock price of $0.76 is trading 32.7% below its estimated GF Value™ of $1.13.
GuruFocus considers Envoy Medical to be Possible Value Trap.
Key valuation signals for COCH:
EBIT per Share: $-0.81
GF Value™: $1.13 vs. price of $0.76 (32.7% below fair value)
No single metric tells the full story. See the COCH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Envoy Medical Inc is a hearing health company focused on providing medical technologies across the hearing loss spectrum. Its product portfolio comprises: the Esteem FI-AMEI, a fully implanted active middle ear implant (FI -AMEI) that works with the ear's natural anatomy, and is FDA-approved for adults with moderate to severe sensorineural hearing loss; and Acclaim CI, an investigational cochlear implant under development. The company derives all of its revenue substantially from the sale of the Esteem FI-AMEI implants and their replacement components. It has one reportable segment: hearing.
24GF Score
Get the complete analysis for COCH
EBIT per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
COCH has been successfully added to your 
